These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 17017913)
41. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Castello MA; Soriano S Ageing Res Rev; 2014 Jan; 13():10-2. PubMed ID: 24252390 [TBL] [Abstract][Full Text] [Related]
42. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Golde TE; Petrucelli L; Lewis J Exp Neurol; 2010 Jun; 223(2):252-66. PubMed ID: 19716367 [TBL] [Abstract][Full Text] [Related]
43. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors. Takeda S Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962 [TBL] [Abstract][Full Text] [Related]
44. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Lal R; Lin H; Quist AP Biochim Biophys Acta; 2007 Aug; 1768(8):1966-75. PubMed ID: 17553456 [TBL] [Abstract][Full Text] [Related]
45. SH2B1 is Involved in the Accumulation of Amyloid-β42 in Alzheimer's Disease. Shen Y; Xia Y; Meng S; Lim NK; Wang W; Huang F J Alzheimers Dis; 2017; 55(2):835-847. PubMed ID: 27802221 [TBL] [Abstract][Full Text] [Related]
46. Intracellular Aβ and its Pathological Role in Alzheimer's Disease: Lessons from Cellular to Animal Models. Ji L; Zhao X; Lu W; Zhang Q; Hua Z Curr Alzheimer Res; 2016; 13(6):621-30. PubMed ID: 27001677 [TBL] [Abstract][Full Text] [Related]
47. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Casas C; Sergeant N; Itier JM; Blanchard V; Wirths O; van der Kolk N; Vingtdeux V; van de Steeg E; Ret G; Canton T; Drobecq H; Clark A; Bonici B; Delacourte A; Benavides J; Schmitz C; Tremp G; Bayer TA; Benoit P; Pradier L Am J Pathol; 2004 Oct; 165(4):1289-300. PubMed ID: 15466394 [TBL] [Abstract][Full Text] [Related]
48. Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Kawahara M Curr Pharm Des; 2010; 16(25):2779-89. PubMed ID: 20698821 [TBL] [Abstract][Full Text] [Related]
49. Amyloid accumulation is a late event in sporadic Alzheimer's disease-like pathology in nontransgenic rats. Stefanova NA; Muraleva NA; Korbolina EE; Kiseleva E; Maksimova KY; Kolosova NG Oncotarget; 2015 Jan; 6(3):1396-413. PubMed ID: 25595891 [TBL] [Abstract][Full Text] [Related]
50. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Hirata-Fukae C; Li HF; Hoe HS; Gray AJ; Minami SS; Hamada K; Niikura T; Hua F; Tsukagoshi-Nagai H; Horikoshi-Sakuraba Y; Mughal M; Rebeck GW; LaFerla FM; Mattson MP; Iwata N; Saido TC; Klein WL; Duff KE; Aisen PS; Matsuoka Y Brain Res; 2008 Jun; 1216():92-103. PubMed ID: 18486110 [TBL] [Abstract][Full Text] [Related]
51. [Involvement of beta-amyloid in the etiology of Alzheimer's disease]. Tomiyama T Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873 [TBL] [Abstract][Full Text] [Related]
52. Peptides as Potential Therapeutics for Alzheimer's Disease. Ribarič S Molecules; 2018 Jan; 23(2):. PubMed ID: 29385735 [TBL] [Abstract][Full Text] [Related]
53. Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and Aβ pathology and modulates Aβ oligomerization. Teng E; Taylor K; Bilousova T; Weiland D; Pham T; Zuo X; Yang F; Chen PP; Glabe CG; Takacs A; Hoffman DR; Frautschy SA; Cole GM Neurobiol Dis; 2015 Oct; 82():552-560. PubMed ID: 26369878 [TBL] [Abstract][Full Text] [Related]
54. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models. Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876 [TBL] [Abstract][Full Text] [Related]